These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26683023)

  • 1. Novel rapid liquid chromatography tandem masspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state.
    Vikingsson S; Strömqvist M; Svedberg A; Hansson J; Höiom V; Gréen H
    Biomed Chromatogr; 2016 Aug; 30(8):1234-9. PubMed ID: 26683023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma.
    Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
    J Pharm Biomed Anal; 2014 Jan; 88():630-5. PubMed ID: 24216282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: application to a human pharmacokinetic study.
    Bihan K; Sauzay C; Goldwirt L; Charbonnier-Beaupel F; Hulot JS; Funck-Brentano C; Zahr N
    Ther Drug Monit; 2015 Feb; 37(1):132-6. PubMed ID: 24977381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients.
    Alvarez JC; Funck-Brentano E; Abe E; Etting I; Saiag P; Knapp A
    J Pharm Biomed Anal; 2014 Aug; 97():29-32. PubMed ID: 24814993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS.
    Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
    Bioanalysis; 2014; 6(23):3215-24. PubMed ID: 25529888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
    Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel and sensitive UPLC-MS/MS method for quantification of sofosbuvir in human plasma: application to a bioequivalence study.
    Rezk MR; Basalious EB; Amin ME
    Biomed Chromatogr; 2016 Sep; 30(9):1354-62. PubMed ID: 26821881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
    Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 889-890():144-7. PubMed ID: 22386128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
    Rousset M; Titier K; Bouchet S; Dutriaux C; Pham-Ledard A; Prey S; Canal-Raffin M; Molimard M
    Clin Chim Acta; 2017 Jul; 470():8-13. PubMed ID: 28412197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.
    Krens SD; van der Meulen E; Jansman FGA; Burger DM; van Erp NP
    Biomed Chromatogr; 2020 Mar; 34(3):e4758. PubMed ID: 31758580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/naloxone formulation.
    Moreno-Vicente R; Fernández-Nieva Z; Navarro A; Gascón-Crespí I; Farré-Albaladejo M; Igartua M; Hernández RM; Pedraz JL
    J Pharm Biomed Anal; 2015 Oct; 114():105-12. PubMed ID: 26037158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid chromatography-tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device.
    Wiesen MH; Farowski F; Feldkötter M; Hoppe B; Müller C
    J Chromatogr A; 2012 Jun; 1241():52-9. PubMed ID: 22552204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the novel antiarrhythmic drug sulcardine sulfate in human plasma by liquid chromatography tandem mass spectrometry and its application in a clinical pharmacokinetic study.
    Jia J; Liu G; Zhang M; Lu Y; Lu C; Liu Y; Zheng H; Wang W; Gui Y; Yu C; Li S; Wang Y
    Biomed Chromatogr; 2016 Aug; 30(8):1291-6. PubMed ID: 26715470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study.
    Rodamer M; Elsinghorst PW; Kinzig M; Gütschow M; Sörgel F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(11-12):695-706. PubMed ID: 21367676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of Cloretazine (VNP40101M) and its active metabolite (VNP4090CE) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).
    Bai F; Minkin P; Fraga CH; O'Shaughnessy MA; Gururangan S; Stewart CF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 853(1-2):97-104. PubMed ID: 17446145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma.
    Svedberg A; Gréen H; Vikström A; Lundeberg J; Vikingsson S
    J Pharm Biomed Anal; 2015 Mar; 107():186-95. PubMed ID: 25594896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry--evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile ester-containing drug.
    Zeng J; Onthank D; Crane P; Unger S; Zheng N; Pasas-Farmer S; Arnold M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):77-84. PubMed ID: 17280881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of cyclizine and norcyclizine in human plasma by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
    Jensen BP; Vella-Brincat JW; Begg EJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Mar; 879(9-10):605-9. PubMed ID: 21333615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UPLC-MS/MS determination of voriconazole in human plasma and its application to a pharmacokinetic study.
    Wang Z; Huang CK; Sun W; Xiao C; Wang ZS
    Biomed Chromatogr; 2015 Feb; 29(2):188-93. PubMed ID: 24925071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of anacetrapib, stable-isotope labeled-anacetrapib (microdose), and four metabolites in human plasma using liquid chromatography tandem mass spectrometry.
    Chavez-Eng CM; Lutz RW; Li H; Goykhman D; Bateman KP; Woolf E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1011():204-14. PubMed ID: 26773885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.